"3T is tackling one of the toughest challenges in immuno-oncology: delivering potent, selective TCR therapies for solid tumors," said Dr. Knudsen. "The science is compelling, and the opportunity for ...
Captain T Cell GmbH has successfully closed an equity financing round to support its T-cell receptor (TCR) T-cell therapies for solid tumors. The company’s autologous lead program, CTC-127, is a ...
Over the past few decades, the idea of modifying a patient’s own immune cells to recognize and destroy cancer has evolved from concept to reality. So-called “adoptive T cell therapy” has emerged as ...
1d
World-renowned Immunologist and Distinguished Scientist Joins CancerVax as Senior Scientific Advisor
Dr. Mark Davis, discoverer of the first T-cell receptor genes and Stanford Professor, to advise the Company on immunological strategies for its novel cancer treatment platformLehi Utah, Jan. 07, 2026 ...
Scientists at École Polytechnique Fédérale Lausanne (EPFL), and at UNIL-CHUV, University Hospital Lausanne (CHUV) and University of Lausanne (UNIL) have developed a computational method to create ...
Hope for adults and children with cancers Camilla Jandus' team is currently preparing a clinical trial of TCR-engineered CD4-based cell therapy. The trial will include different types of cancer ...
Researchers at the Johns Hopkins Kimmel Cancer Center's Ludwig Center developed a new treatment that selectively targets ...
Immatics has innovative TCR therapies, strong cash position, and expanding clinical pipeline targeting solid tumors. Read for ...
Lymphatic malformations (LMs) are congenital vascular anomalies characterized by abnormal lymphatic development, leading to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback